comparemela.com

Latest Breaking News On - Dupilumab - Page 3 : comparemela.com

Anti-allergy Drug Dupilumab Treats Lung Cancer

Researchers found a pathway linked to allergies that, when blocked, triggers antitumor immunity in lung cancer mouse models.

Icahn school of medicine at mount sinaiIcahn schoolMount sinaiLung cancerNon small cell lung cancerLung cancer treatmentAllergy drug

Data From Phase 3 Trials Demonstrate Efficacy of Dupilumab for Treating COPD, Type 2 Inflammation

Patients with uncontrolled chronic obstructive pulmonary disease (COPD) and type 2 inflammation had significantly better lung function at least a year into a dupilumab regimen.

Ivelin radkovNaimish patelGeorged yancopoulosEuropean medicines agencyGlobal developmentPhase 3 trialsType 2 inflammation

Gil Yosipovitch, MD: Overview of Current Research on Prurigo Nodularis

During this interview segment, Dr. Yosipovitch discussed his overview of current PN research and a specific study he had presented at EADV.

Gil yosipovitchMiller school of medicineUniversity of miamiEuropean academy of dermatologyMiller schoolPrurigo nodularis

Dupilumab Shown to Reduce COPD Exacerbations Substantially in New Phase 3 Data

This data from the NOTUS trial is set to be submitted to the FDA alongside the phase 3 BOREAS trial data later in the year.

Georged yancopoulosNaimish patelRegeneron pharmaceuticals incDrug administrationRegeneron pharmaceuticalsBreakthrough therapySignificantly reducedSecond positive phaseConfirming potentialBecome first approved biologicPhase 3

Gil Yosipovitch, MD: New Analysis of Data on Patient Satisfaction with Dupilumab for Prurigo Nodularis

This discussion with Dr. Yosipovitch covered findings presented at EADV 2023 on dupilumab and prurigo nodularis patients’ satisfaction.

Gil yosipovitchEuropean academy of dermatologyUniversity of miamiMiller school of medicineMiller schoolNature medicinePrurigo nodularis

vimarsana © 2020. All Rights Reserved.